治疗小细胞肺癌新药——Lurbinectedin

New drug in treatment of small cell lung cancer——Lurbinectedin

小细胞肺癌是一种致死性很高的疾病,具有早期转移和进展迅速的特征,且复发后缺乏有效的治疗方法。2020年6月,美国食品和药物管理局批准Lurbinectedin用于接受铂类药物基础疗法期间或之后出现疾病进展的转移性小细胞肺癌成年患者的治疗。Lurbinectedin是一种烷化剂,可与DNA小沟中的鸟嘌呤残基相结合,触发系列反应,最终导致细胞凋亡,从而发挥抗癌作用。本文对Lurbinectedin的作用机制、药代动力学、临床研究和安全性等进行综述。

Small cell lung cancer is a highly lethal disease,characterized by early metastasis and rapid growth,and no effective treatment after relapse.In June 2020,Lurbinectedin was approved by the U.S.Food and Drug Adiministration for the treatment of adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy.Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA,triggers a cascade of events and eventually results the cell death,so as to play an anticancer effect.This article reviewed the mechanism,pharmacokinetics,clinical trials,and safety of Lurbinectedin.